Last year was truly special for MannKind (NASDAQ: MNKD Afrezza's mammoth opportunity The drug in question, Afrezza, is an inhaled therapy designed to help control glycemic balance in both type 1 and type 2 diabetics. The market potential is huge, ... Motley Fool, 2 weeks ago
In celebration of the 10sec app release, all transaction fees are free!COMPLETELY FREE! NO HIDDEN COSTS!10sec is the fastest, simplest way to buy and sell anything with your smartphone.10sec does not limit uploads to any one category. Anything ...ZDNet, 1 month ago
on your WebpageAdd Widget >Get your members hooked!